Lexeo Therapeutics, Inc. LXEO
Updated: 9 Aug 2026
No signal published yet
We already track Lexeo Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Lexeo Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Lexeo Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 5, 2026, Lexeo Therapeutics announced that the U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to its gene therapy candidate LX2020. The designation was based on interim clinical data from the ongoing HEROIC-PKP2 Phase I/II trial for PKP2-associated arrhythmogenic cardiomyopathy.
What Firelda Watch includes for Lexeo Therapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Lexeo Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Lexeo Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more